Isoprenaline Only Product

ApprovedSmall molecule

UUniversity of Southern Denmark

Isoprenaline Only Product is one of 40 small molecule programs targeting Cardiac Arrest. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiac ArrestActive, not recruiting

Cardiac ArrestApproved

Active, not recruiting

Competition

Competitive Landscape

89 competitors in Cardiac Arrest

#DrugCompanyPhaseTrials

Tofranil

Sanofi

Phase 3

1 2

Tnkase

Roche

Phase 3

1 3

Cordarone

WWyeth-Lederle Vaccines

Phase 3

6 4

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

—5

Esmeron

FFresenius Kabi Oncology Ltd.

Phase 3

3 6

Quinidine Gluconate

WWyeth-Lederle Vaccines

Phase 3

1 7

Xylocaine

MMEDRx USA, Inc.

Phase 3

1 8

Zyprexa

MMODAG GmbH

Phase 3

1 9

Mexitil

Boehringer Ingelheim

Phase 3

1 10

Decadron

AAspen Global Incorporated

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Post-ApprovalNot yet recruiting

Cardiac Arrest

NCT06473116

Clinical

Trials by Indication[1]

Cardiac Arrest1 trial

Epinephrine Versus Isoprenaline During Out-of-Hospital Cardiac Arrest With Asystole

Not yet recruiting·UUniversity of Southern Denmark·Phase 4·NCT06473116·1,178 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Isoprenaline Only Product. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Isoprenaline Only Product compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Isoprenaline Only Product. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Southern Denmark company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of Southern Denmark

Isoprenaline Only Product

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Cardiac Arrest1 trial

References

Drug Info

Quick Facts

Related News